OptiBiotix Health has entered into a manufacturing and supply agreement with Sacco Srl.
This granted Sacco with exclusive licence to manufacture and supply OptiBiotix’s cholesterol reducing strain, LPLDL, in Europe in return for 50% of the profit with a minimum price per kg to secure against discounting.
Under the terms of the agreement, Sacco would promote and expand the supply of LPLDL throughout Europe on the maximum possible scale bringing it to the attention of as many buyers as possible.
LPLDL would be supplied by Sacco as a raw ingredient to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into a wide range of final formulations and presentations.
Story provided by StockMarketWire.com